Kiromic Biopharma Inc's Customers Performance

Name: Kiromic Biopharma Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

KRBP

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


KRBP's Source of Revenues		• List of KRBP Customers

for the same period Kiromic Biopharma Inc

• List of KRBP Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Kiromic Biopharma Inc's Comment on Sales, Marketing and Customers

News about Kiromic Biopharma Inc Contracts

Pioneering Cancer Treatment Kiromic BioPharma Reports Encouraging Results from Deltacel-01 Clinical Trial

In the realm of oncology, where the fight against cancer is relentless and innovation is paramount, Kiromic BioPharma, Inc. (OTCQB: KRBP) recently published notable findings from its Deltacel-01 clinical trial. With the announcement that the fourth patient enrolled in this study has achieved an impressive 10-month progression-free survival (PFS), the implications of these results not only underline the potential of their therapeutic approach but also represent a pivotal moment for the company itself. Understanding Deltacel-01 The Deltacel-01 trial is a Phase 1 clinical study aimed at assessing the efficacy of Deltacel (KB-GDT-01), a revolutionary allogeneic Gamma Delta T-cell (GDT) therapy. This innovative ...

Kiromic BioPharmas Deltacel A Promising Leap in the Fight Against Metastatic Lung Cancer with FDA Fast Track Designa...

Kiromic BioPharma s Deltacel: A Promising Leap in the Fight Against Metastatic Lung Cancer with FDA Fast Track Designation In a significant advancement for oncology, Kiromic BioPharma, Inc. (OTCQB: KRBP) has announced that its innovative therapy, Deltacel (KB-GDT-01), has received FDA Fast Track designation. This designation is a critical milestone in the development of Deltacel, an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy aimed at treating patients with metastatic non-small cell lung cancer (NSCLC) who have shown progression after multiple lines of treatment.The Fast Track designation facilitates greater access to the regulatory processes for therapies demonstrating the potential to addres...

Promising Results of Kiromic BioPharmas Deltacel-01 Clinical Trial in NSCLC Patients

for CSIMarket.com :Houston-based biopharmaceutical company, Kiromic BioPharma, has announced favorable safety, tolerability, and early efficacy results in the fourth patient of their Deltacel-01 Phase 1 clinical trial. The trial entails evaluating Kiromic s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, known as Deltacel (KB-GDT-01), in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have previously failed standard therapies.The preliminary results obtained from this ongoing clinical trial are promising, indicating the potential of Deltacel-01 as an innovative treatment solution for patients with advanced NSCLC. The therapy aims to harness the body s immune system by ...

KRBP's Stock Performance relative to it's Customers

KRBP's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Kiromic Biopharma Inc	0.00	0.00	-26.90	16
SUBTOTAL	0.00	0.00	0.00	-

Sources: Kiromic Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kiromic Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kiromic Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.